ATE424386T1 - Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten - Google Patents

Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten

Info

Publication number
ATE424386T1
ATE424386T1 AT05817767T AT05817767T ATE424386T1 AT E424386 T1 ATE424386 T1 AT E424386T1 AT 05817767 T AT05817767 T AT 05817767T AT 05817767 T AT05817767 T AT 05817767T AT E424386 T1 ATE424386 T1 AT E424386T1
Authority
AT
Austria
Prior art keywords
prostaglandin
treatment
mediated diseases
pyridine compounds
pyridine
Prior art date
Application number
AT05817767T
Other languages
English (en)
Inventor
Gerard Giblin
Adrian Hall
David Hurst
Derek Rawlings
Tiziana Scoccitti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35735391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE424386(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0428263A external-priority patent/GB0428263D0/en
Priority claimed from GB0508458A external-priority patent/GB0508458D0/en
Priority claimed from GB0524675A external-priority patent/GB0524675D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE424386T1 publication Critical patent/ATE424386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05817767T 2004-12-23 2005-12-21 Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten ATE424386T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0428263A GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds
GB0508458A GB0508458D0 (en) 2005-04-26 2005-04-26 Compounds
GB0524675A GB0524675D0 (en) 2005-12-02 2005-12-02 Compounds

Publications (1)

Publication Number Publication Date
ATE424386T1 true ATE424386T1 (de) 2009-03-15

Family

ID=35735391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05817767T ATE424386T1 (de) 2004-12-23 2005-12-21 Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten

Country Status (20)

Country Link
US (2) US20100137378A1 (de)
EP (2) EP2053042A1 (de)
JP (1) JP2008525363A (de)
KR (1) KR20070091301A (de)
AR (1) AR052429A1 (de)
AT (1) ATE424386T1 (de)
AU (1) AU2005318372A1 (de)
BR (1) BRPI0519398A2 (de)
CA (1) CA2592442A1 (de)
DE (1) DE602005013116D1 (de)
EA (2) EA200701324A1 (de)
ES (1) ES2321535T3 (de)
IL (1) IL183781A0 (de)
MA (1) MA29082B1 (de)
MX (1) MX2007007830A (de)
NO (1) NO20073332L (de)
PE (2) PE20060838A1 (de)
TW (1) TW200640865A (de)
UY (1) UY29298A1 (de)
WO (1) WO2006066968A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608825D0 (en) * 2006-05-04 2006-06-14 Glaxo Group Ltd Compounds
US8193194B2 (en) * 2007-05-25 2012-06-05 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
CA2768492A1 (en) 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2570125A1 (de) * 2011-09-16 2013-03-20 Almirall, S.A. EP1-Rezeptorliganden
TR201816624T4 (tr) 2014-06-03 2018-11-21 Idorsia Pharmaceuticals Ltd Pirazol bileşikleri ve t tipi kalsiyum kanalı bloke edicileri olarak kullanımları.
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
PT3519401T (pt) 2016-09-30 2021-12-27 Vertex Pharma Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
MA49114A (fr) 2016-12-16 2020-03-25 Idorsia Pharmaceuticals Ltd Combinaison pharmaceutique comprenant un bloqueur de canal calcique de type t
EP3577099B1 (de) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd Ein neues verfahren zur herstellung von 1-aryl-1-trifluormethylcyclopropanen
EP3634402B1 (de) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Verfahren zur behandlung von zystischer fibrose
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2021174475A1 (en) * 2020-03-05 2021-09-10 Givaudan Sa Organic compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1471276A (en) 1975-01-22 1977-04-21 Nippon Shinyaku Co Ltd 5-benzylpicolinic acid deri vatives
EP0388682A1 (de) 1989-03-15 1990-09-26 Bayer Ag Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1995017888A1 (en) 1993-12-30 1995-07-06 Smithkline Beecham Corporation Phenylmethyl hexanamides, and the use thereof
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
PL185544B1 (pl) 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
EP0752421B1 (de) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
DK1288206T3 (da) 1996-04-12 2008-11-24 Searle Llc Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
EE03680B1 (et) 1996-07-18 2002-04-15 Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE317845T1 (de) 1997-09-05 2006-03-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6605624B1 (en) 1998-02-13 2003-08-12 Pharmacia Corporation Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
JP2002538157A (ja) 1999-02-27 2002-11-12 グラクソ グループ リミテッド ピラゾロピリジン
ES2213601T3 (es) 1999-09-14 2004-09-01 MERCK FROSST CANADA & CO. Acidos carboxilicos y acilsulfonamidas, composiciones que contienen tales compuestos y procedimiento de tratamiento.
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
MXPA04009800A (es) 2002-04-08 2004-12-13 Glaxo Group Ltd Acido (2-((2-alcoxi)-fenil)-ciclopent-1-enil) carbociclico y heterociclico aromatico y derivados.
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
WO2004039807A1 (en) 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine and pyridoindolizine derivatives
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
GB0306329D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
GB0323584D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
GB0323585D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
DE602004011966T2 (de) 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
GB0328024D0 (en) 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
GB0410121D0 (en) 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP2053042A1 (de) 2009-04-29
PE20060838A1 (es) 2006-10-12
TW200640865A (en) 2006-12-01
IL183781A0 (en) 2007-09-20
EA200701324A1 (ru) 2007-10-26
AR052429A1 (es) 2007-03-21
KR20070091301A (ko) 2007-09-10
WO2006066968A1 (en) 2006-06-29
PE20081440A1 (es) 2008-12-31
UY29298A1 (es) 2006-05-31
MA29082B1 (fr) 2007-12-03
DE602005013116D1 (de) 2009-04-16
AU2005318372A1 (en) 2006-06-29
US20100137378A1 (en) 2010-06-03
NO20073332L (no) 2007-09-17
EP1833795A1 (de) 2007-09-19
US20080249138A1 (en) 2008-10-09
EA200801909A1 (ru) 2009-06-30
MX2007007830A (es) 2007-07-25
US7759369B2 (en) 2010-07-20
CA2592442A1 (en) 2006-06-29
EP1833795B1 (de) 2009-03-04
JP2008525363A (ja) 2008-07-17
ES2321535T3 (es) 2009-06-08
BRPI0519398A2 (pt) 2009-01-20

Similar Documents

Publication Publication Date Title
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
HUE050998T2 (hu) Gyógyszerek fibrotikus betegségek kezelésére
ATE432273T1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
DE602005015963D1 (de) Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties